23 June 2016 
EMA/CHMP/421658/2016  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Nevanac 
nepafenac 
On 23 June 2016 last day of the CHMP meeting, the Committee for Medicinal Products for Human Use 
(CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for 
the medicinal product Nevanac. The marketing authorisation holder for this medicinal product is Alcon 
Laboratories (UK) Ltd. 
Nevanac is available as eye drops in two different strengths, 1 mg/ml and 3 mg/ml. The CHMP adopted a 
new indication for the 3 mg/ml strength as follows: 
“Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic 
patients.” 
For information, the full indications for Nevanac 3mg/ml will be as follows: 
“Nevanac 3 mg/ml is indicated in adults for:2 
• 
Prevention and treatment of postoperative pain and inflammation associated with cataract surgery 
•  Reduction in the risk of postoperative macular oedema associated with cataract surgery in 
diabetic patients (see section 5.1)” 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
